Your browser doesn't support javascript.
loading
How Can the EU Beating Cancer Plan Help in Tackling Lung Cancer, Colorectal Cancer, Breast Cancer and Melanoma?
Horgan, Denis; Baird, Anne-Marie; Middleton, Mark; Mihaylova, Zhasmina; Van Meerbeeck, Jan P; Vogel-Claussen, Jens; Van Schil, Paul E; Malvehy, Josep; Ascierto, Paolo Antonio; Dube, France; Zaiac, Michael; Lal, Jonathan A; Kaminska-Winciorek, Grazyna; Donia, Marco; André, Thierry; Kozaric, Marta; Osterlund, Pia; Dumitrascu, Dan Lucian; Bertolaccini, Luca.
Affiliation
  • Horgan D; European Alliance for Personalised Medicine, 1040 Brussels, Belgium.
  • Baird AM; Department of Molecular and Cellular Engineering, Jacob Institute of Biotechnology and Bioengineering, Faculty of Engineering and Technology, Sam Higginbottom University of Agriculture, Technology and Sciences, Prayagraj 211007, India.
  • Middleton M; Lung Cancer Europe, 3008 Bern, Switzerland.
  • Mihaylova Z; School of Medicine, Trinity Translational Medicine Institute, Trinity College Dublin, Dublin 2, Ireland.
  • Van Meerbeeck JP; Department of Oncology, Cancer Research UK Oxford Centre, University of Oxford, Oxford OX3 7DQ, UK.
  • Vogel-Claussen J; Department of Medical Oncology, Military Medical Academy, 1000 Sofia, Bulgaria.
  • Van Schil PE; Department of Thoracic Oncology, Antwerp University Hospital, 2650 Edegem, Belgium.
  • Malvehy J; Department of Diagnostic and Interventional Radiology, Hannover Medical School, 30625 Hannover, Germany.
  • Ascierto PA; Biomedical Research in Endstage and Obstructive Lung Disease Hannover (BREATH), German Center for Lung Research (DZL), Hannover Medical School, 30625 Hannover, Germany.
  • Dube F; Department of Thoracic and Vascular Surgery, Antwerp University Hospital, Antwerp University, 2650 Antwerp, Belgium.
  • Zaiac M; Melanoma Unit, Dermatology Department Hospital Clinic, University of Barcelona, 08036 Barcelona, Spain.
  • Lal JA; IDIBAPS, CIBER de Enfermedades Raras, Instituto Carlos III, 28029 Madrid, Spain.
  • Kaminska-Winciorek G; Unit of Melanoma, Cancer Immunotherapy and Development Therapeutics, Istituto Nazionale Tumori IRCCS Fondazione "G. Pascale", 80131 Naples, Italy.
  • Donia M; Astra Zeneca, 1800 Concord Pike, Wilmington, DE 19803, USA.
  • André T; Novartis Farma SpA, 21040 Origgio, Italy.
  • Kozaric M; Department of Molecular and Cellular Engineering, Jacob Institute of Biotechnology and Bioengineering, Faculty of Engineering and Technology, Sam Higginbottom University of Agriculture, Technology and Sciences, Prayagraj 211007, India.
  • Osterlund P; Institute for Public Health Genomics, Department of Genetics and Cell Biology, GROW School of Oncology and Developmental Biology, Faculty of Health, Medicine and Life Sciences, Maastricht University, 6229 ER Maastricht, The Netherlands.
  • Dumitrascu DL; Department of Bone Marrow Transplantation and Hematology-Oncology, Skin Cancer and Melanoma Team, M. Sklodowska-Curie National Research Institute of Oncology, 44-101 Gliwice, Poland.
  • Bertolaccini L; National Center for Cancer Immune Therapy, Department of Oncology, Copenhagen University Hospital, 2730 Herlev, Denmark.
Healthcare (Basel) ; 10(9)2022 Aug 25.
Article in En | MEDLINE | ID: mdl-36141230
ABSTRACT
Cancer is the second leading cause of mortality in EU countries, and the needs to tackle cancer are obvious. New scientific understanding, techniques and methodologies are opening up horizons for significant improvements in diagnosis and care. However, take-up is uneven, research needs and potential outstrip currently available resources, manifestly beneficial practices-such as population-level screening for lung cancer-are still not generalised, and the quality of life of patients and survivors is only beginning to be given attention it merits. This paper, mainly based on a series of multistakeholder expert workshops organised by the European Alliance for Personalised Medicine (EAPM), looks at some of those specifics in the interest of planning a way forward. Part of this exercise also involves taking account of the specific nature of Europe and its constituent countries, where the complexities of planning a way forward are redoubled by the wide variations in national and regional approaches to cancer, local epidemiology and the wide disparities in health systems. Despite all the differences between cancers and national and regional resources and approaches to cancer care, there is a common objective in pursuing broader and more equal access to the best available care for all European citizens.
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Aspects: Patient_preference Language: En Journal: Healthcare (Basel) Year: 2022 Document type: Article Affiliation country:

Full text: 1 Collection: 01-internacional Database: MEDLINE Aspects: Patient_preference Language: En Journal: Healthcare (Basel) Year: 2022 Document type: Article Affiliation country: